EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolic Signatures in Lean MASLD: Current Insights and Future Directions

Ambrin Farizah Babu iD

Metabolites · 31.08.2025 · 15 (9) · 583

DOI: 10.3390/metabo15090583 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 31.08.2025. Verfasst von Ambrin Farizah Babu. Beteiligte Einrichtung: School of Medicine, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, 70211 Kuopio, Finland. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Finnish Cultural Foundation, Jenny ja Antti Wihurin Rahasto, Jenny and Antti Wihuri Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lean metabolic dysfunction-associated steatotic liver disease (lean MASLD) challenges longstanding views that link hepatic steatosis primarily to obesity. Emerging as a distinct and under-recognized clinical entity, lean MASLD affects individuals with a normal body mass index (BMI), yet carries risks of cardiovascular disease, hepatocellular carcinoma, and liver-related mortality comparable to obesity-associated MASLD. The absence of overt metabolic dysfunction complicates diagnosis, revealing critical limitations in current screening frameworks centered on BMI. This review synthesizes evolving clinical insights and epidemiological trends in lean MASLD, and delineates its unique pathophysiological mechanisms. Recent advances in metabolomics have uncovered disease-specific disruptions in lipid and amino acid metabolism, bile acid signaling, and gut microbiota-derived metabolites. By integrating evidence from metabolic, genetic, and epigenetic domains, we identified promising biomarkers, and therapeutic targets that may support earlier detection and precision-guided treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

body mass indexgenetic and epigenetic modifiersgut microbial metaboliteslean metabolic dysfunction-associated steatotic liver diseaselipidomicsmetabolomicsnon-alcoholic fatty liver disease

Autor:innen und Institutionen

  • School of Medicine, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, 70211 Kuopio, Finland.
  • Food Sciences Unit, Department of Life Technologies, University of Turku, 20014 Turku, Finland.

ORCID-Profile: Ambrin Farizah Babu

Förderung

  • Finnish Cultural Foundation
  • Jenny ja Antti Wihurin Rahasto
  • Jenny and Antti Wihuri Foundation

Zitieren

APA

Babu, A. F. (2025). Metabolic Signatures in Lean MASLD: Current Insights and Future Directions. Metabolites, 15(9), 583. https://doi.org/10.3390/metabo15090583

Vancouver

Babu AF. Metabolic Signatures in Lean MASLD: Current Insights and Future Directions. Metabolites. 2025;15(9):583. doi:10.3390/metabo15090583

BibTeX
@article{Babu2025,
  author = {Babu, Ambrin Farizah},
  title = {Metabolic Signatures in Lean MASLD: Current Insights and Future Directions},
  journal = {Metabolites},
  year = {2025},
  volume = {15},
  number = {9},
  pages = {583},
  doi = {10.3390/metabo15090583}
}
Kostenlos starten →